Weight-Loss Drugs Reshape US Cannabis Market

The U.S. cannabis market, valued at $40 billion, is undergoing a significant transformation due to the surging popularity of GLP-1 weight-loss drugs. Experts and industry executives observe that these therapies are altering consumer behavior, leading to diminished cravings and shifting preferences, particularly concerning appetite-driven 'munchies' associated with cannabis use.

Cannabis retailers are responding to these changes by adjusting their product offerings. For instance, some dispensaries are now recommending lower-dose edibles, vapes, and tinctures to customers who are on GLP-1 medications. This adjustment is partly due to the way GLP-1 therapies slow gastric emptying, which can delay the effects of edibles and potentially lead to unintended stronger experiences if consumers redose too soon.

Scientific inquiry into the relationship between GLP-1 drugs and cannabis is intensifying. The National Institute on Drug Abuse is sponsoring a clinical trial to evaluate tirzepatide for cannabis use disorder. Preliminary retrospective analyses of health records suggest potential benefits for diabetic patients on GLP-1 drugs regarding cannabis use disorder outcomes. Further clinical trials are anticipated later this year.

Consumer behavior may also be shifting as some individuals reportedly substitute cannabis for alcohol or use it intentionally for sleep or stress management. Additionally, there's growing consumer interest in the connection between cannabis and metabolism, with inquiries about appetite suppression and low-hunger edibles increasing. However, industry insiders caution that much of the current evidence remains anecdotal, with many factors influencing the interactions.